Appointment dossier — Prostate Adenocarcinoma
Bring this to your appointment. It summarizes what published studies report — it is not medical advice and does not say anything works. Decisions are yours and your care team’s.
Compounds studied in Prostate Adenocarcinoma
- Cisplatin — Review evidence · 1 positive / 1 negative-mixed · PMID 33413292, 18408396
- Etoposide — Review evidence · 1 positive / 1 negative-mixed · PMID 33413292, 37485216, 18408396
- Carboplatin — Review evidence · 0 positive · PMID 37485216
- Durvalumab — Review evidence · 0 positive · PMID 37485216
“Positive” means a study reported a positive result — most are early lab/animal work that may not translate to people.
Open recruiting trials (18)
- NCT04175431 · Phase 2 — Prostate Specific Membrane Antigen (PSMA) or (FACBC) PET/CT Site-Directed Therapy for Treatment of Prostate Cancer, Flu-BLAST-PC Study (United States)
- NCT06145633 · Phase 2 — Vorinostat and 177Lu-PSMA-617 for the Treatment of PSMA-Low Metastatic Castration-Resistant Prostate Cancer (United States)
- NCT06330805 · Phase 2 — Effects of Relugolix vs Leuprolide on Cardiac Function in Patients With Prostate Cancer (United States)
- NCT05691465 · Phase 2 — Testing the Safety and Effectiveness of Radiation-based Treatment (Lutetium Lu 177 Dotatate) for Metastatic Prostate Cancer That Has Neuroendocrine Cells (United States)
- NCT04704505 · Phase 2 — Bipolar Androgen Therapy (BAT) and Radium-223 (RAD) in Metastatic Castration-resistant Prostate Cancer (mCRPC) (United States)
- NCT07179783 · Phase 2 — Sacituzumab Tirumotecan in Combination With Tagitanlimab in the Treatment of Aggressive Variant Prostate Cancer (AVPC) and Neuroendocrine Prostate Cancer (NEPC) (China)
- NCT03821246 · Phase 2 — Neoadjuvant Atezolizumab-Based Combination Therapy in Men With Localized Prostate Cancer Prior to Radical Prostatectomy (United States)
- NCT06257693 · Phase 1 — Enzalutamide Implants (Enolen) in Patients With Prostate Cancer (United States)
- NCT06044857 · Phase 1 — PSMA PET Response Guided SabR in High Risk Pca (United States)
- NCT05983432 · Phase 1 — Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors (United States)
- NCT03880422 — Nutrition and Exercise Interventions for Androgen Deprivation Therapy-Induced Obese Frailty in Elderly and Non-Elderly Survivors of Advanced Prostate Cancer (United States)
- NCT07468903 — Focal Radiation Therapy (HDR-Brachytherapy) for the Treatment of Prostate Cancer (United States)
- NCT04969315 · Phase 1 / Phase 2 — TT-4 and TT-10 as Single Agents and in Combination in Subjects With Advanced Selected Solid Tumors and Pleural Mesothelioma (United States)
- NCT05914116 · Phase 1 / Phase 2 — A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors (United States)
- NCT05349227 — Comprehensive Outcomes for After Cancer Health (United States)
- NCT03258320 · Phase 2 / Phase 3 — A Randomised Trial of Cabazitaxel, Docetaxel, Mitoxantrone or Satraplatin (CDMS) Plus Surgery for Prostate Cancer Patients (China)
- NCT07427043 · Phase 3 — Robotic Opioid-free Prostatectomy Enhanced Strategy (ROPES) (United States)
- NCT07617272 · Phase 2 — Prostate Androgen Response Investigation Using a Stratification BIOmarker; Predicting Prostate Cancer Downstaging by Neoadjuvant Darolutamide With PCAI ImmunoScore (Sweden)
Most-relevant first: trials that name Prostate Adenocarcinoma, then broader trials you may still qualify for. 187 recruiting trials name this cancer on ClinicalTrials.gov. Eligibility is decided by each trial's team — bring these NCT numbers to your appointment.
Financial help to look into
- PAN Foundation — Copay assistance funds by diagnosis (funds open and close as money allows). https://www.panfoundation.org/
- HealthWell Foundation — Copay and premium assistance funds by disease. https://www.healthwellfoundation.org/
- CancerCare — financial assistance — Limited grants plus free financial counseling. https://www.cancercare.org/financial
- Family Reach — Help with everyday living costs (rent, transport, food) during treatment. https://familyreach.org/
- NeedyMeds — Searchable directory of drug patient-assistance and discount programs. https://www.needymeds.org/
For each medicine above, search manufacturer and nonprofit programs at medicineassistancetool.org.
Questions to ask your oncologist
- Of the open trials I found (for example NCT04175431), am I eligible for any — here or at a larger cancer center?
- What is my exact diagnosis — the type, subtype, stage, and grade?
- Has my tumor had molecular or genomic testing (e.g. next-generation sequencing), and what did it find?
- Should I have inherited (germline) genetic testing, and could it affect my treatment or my family?
- What is the goal of treatment for me — cure, long-term control, or comfort?
- What are all of my standard treatment options, and what does each one involve?
- What is the realistic benefit of each option, in actual numbers?
- What are the most common and the most serious side effects, and how are they managed?
- How will we know if treatment is working, and how often will I be scanned or tested?
- If the first treatment doesn't work, what are the next options?
- Are there gentler options if I want to prioritize quality of life?
- Am I eligible for any clinical trials — here or at a larger/academic cancer center?
- Is my case reviewed by a multidisciplinary tumor board?
- Would a second opinion at a center that treats my cancer often be worthwhile?
- Could any of my prescriptions, over-the-counter drugs, or supplements interfere with treatment?
- Which symptoms are emergencies, and who do I call after hours?
- Should I see palliative or supportive care alongside my treatment?
- How will treatment affect my daily life, work, and (if it matters to me) fertility?
- What can I safely do myself — diet and activity — and is anything I'm taking risky?
- What will treatment cost, and is financial assistance available?
- Should my tumor tissue be stored (biobanked) for future testing or trials?